Could NIB shares beat the market in 2024?

Will next year be better for this private health insurer's shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have had an underwhelming time in 2023.

Since the start of the year, the private health insurer's shares have lost 4.5% of their value.

As a comparison, the ASX 200 index is up approximately 7% over the same period.

A man looking at his laptop and thinking.

Image source: Getty Images

Will things be better for NIB shares in 2024?

There are a few factors that could have a major say on how NIB shares perform next year.

The first is the performance of the market as a whole. If interest rates are cut across the globe, it could give investor sentiment a major boost and drive shares higher.

Premium rate increases are another factor that could impact the company's share price. According to reports, the health insurance industry is seeking a 6% premium rate increase on average for next year.

While it is unclear if this will be approved, it is notably higher than what the market was expecting and compares to increases of 2.9% in 2023, 2.7% in 2022, and 2.74% in 2021. Goldman Sachs commented:

The 6% rate increase quoted in the AFR is higher than we expected noting claims cost inflation remains somewhat benign reflecting lower utilisation for mental health and rehab in particular.

What else?

Another factor to be aware of is the potential change to the NDIS.

NIB entered the NDIS market at the end of last year through the acquisition of plan manager, Maple. It raised $158 million to support its entry and has since made a number of other acquisitions, growing its presence in the market.

However, proposed changes to the NDIS could be a blow to its ambitions. A review is expected to be released in 2024.

Can its shares rise?

The good news is that Goldman Sachs has taken all the above into consideration and remains bullish on NIB shares.

It currently has a buy rating and an $8.40 price target on them, which implies a potential upside of 13.5% for investors over the next 12 months.

The broker also expects a fully franked 3.9% dividend yield for FY 2024, boosting the total potential return to approximately 17.5%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »